Cefdinir
Omnicef (cefdinir) is a small molecule pharmaceutical. Cefdinir was first approved as Omnicef on 1997-12-04. It is used to treat bacterial infections, bacterial pneumonia, bacterial skin diseases, bronchitis, and escherichia coli infections amongst others in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cefdinir | ANDA | 2023-06-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bacterial infections | — | D001424 | A49 |
| bacterial pneumonia | EFO_1001272 | D018410 | J15.9 |
| bacterial skin diseases | — | D017192 | — |
| bronchitis | — | D001991 | J40 |
| escherichia coli infections | EFO_1001318 | D004927 | B96.20 |
| haemophilus infections | EFO_1001127 | D006192 | — |
| klebsiella infections | EFO_1001353 | D007710 | — |
| moraxellaceae infections | EFO_1001072 | D045828 | — |
| otitis media | EFO_0004992 | D010033 | H66.9 |
| proteus infections | EFO_1001130 | D011512 | — |
Show 4 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
180 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | 3 | — | 8 | 14 | 6 | 31 |
| Hypertension | D006973 | EFO_0000537 | I10 | 6 | 2 | 7 | 11 | 2 | 28 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | 2 | 6 | 12 | 20 |
| Portal hypertension | D006975 | EFO_0000666 | K76.6 | — | 1 | 4 | 5 | 5 | 14 |
| Esophageal and gastric varices | D004932 | EFO_0009545 | I85 | — | 1 | 1 | 5 | 3 | 9 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 2 | 1 | 3 | 6 |
| Stable angina | D060050 | I20.8 | 3 | — | — | 1 | — | 4 | |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | 3 | — | 3 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | 1 | — | — | 2 | — | 3 |
| Dilated cardiomyopathy | D002311 | EFO_0000407 | I42.0 | — | — | — | 3 | — | 3 |
Show 25 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 4 | 2 | — | — | 7 |
| Cardiotoxicity | D066126 | EFO_1001482 | 1 | 1 | 2 | — | — | 4 | |
| Lymphoma | D008223 | C85.9 | — | 1 | 1 | — | — | 2 | |
| Essential hypertension | D000075222 | I10 | 1 | — | 1 | — | — | 2 | |
| Masked hypertension | D059468 | — | — | 1 | — | — | 1 | ||
| Tricuspid valve insufficiency | D014262 | HP_0005180 | — | — | 1 | — | — | 1 | |
| Abdominal obesity | D056128 | HP_0001956 | — | — | 1 | — | — | 1 | |
| Hepatitis c | D006526 | B19.2 | — | — | 1 | — | — | 1 | |
| Hepatitis b | D006509 | — | — | 1 | — | — | 1 | ||
| Myeloid leukemia acute | D015470 | C92.0 | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary arterial hypertension | D000081029 | 2 | 3 | — | — | — | 3 | ||
| Cocaine-related disorders | D019970 | F14 | — | 2 | — | — | 1 | 3 | |
| Secondary parkinson disease | D010302 | EFO_1001175 | G21 | — | 2 | — | — | — | 2 |
| Rem sleep behavior disorder | D020187 | EFO_0007462 | G47.52 | — | 2 | — | — | — | 2 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 1 | — | — | 1 | 2 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | — | 1 | — | — | — | 1 |
| Cardiovascular abnormalities | D018376 | EFO_0003848 | — | 1 | — | — | — | 1 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | — | — | — | 1 |
| Prostatic neoplasms | D011471 | C61 | — | 1 | — | — | — | 1 | |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 9 | — | — | — | 2 | 11 | ||
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 3 | — | — | — | 1 | 4 |
| Glioblastoma | D005909 | EFO_0000515 | 2 | — | — | — | — | 2 | |
| Heart disease risk factors | D000082742 | 1 | — | — | — | — | 1 | ||
| Sleep deprivation | D012892 | F51.12 | 1 | — | — | — | — | 1 | |
| Sleep wake disorders | D012893 | G47 | 1 | — | — | — | — | 1 | |
| Sleep | D012890 | GO_0030431 | 1 | — | — | — | — | 1 | |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute-on-chronic liver failure | D065290 | — | — | — | — | 2 | 2 | ||
| Hepatocellular carcinoma | D006528 | C22.0 | — | — | — | — | 1 | 1 | |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | — | 1 | 1 |
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | — | — | — | — | 1 | 1 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | — | — | — | 1 | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 1 | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | — | 1 | 1 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | — | — | 1 | 1 |
| Gastrointestinal diseases | D005767 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CEFDINIR |
| INN | cefdinir |
| Description | Cefdinir is a cephalosporin compound having 7beta-2-(2-amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino- and 3-vinyl side groups. It has a role as an antibacterial drug. It is a cephalosporin and a ketoxime. |
| Classification | Small molecule |
| Drug class | cephalosporins |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\O)c3csc(N)n3)[C@H]2SC1 |
Identifiers
| PDB | — |
| CAS-ID | 91832-40-5 |
| RxCUI | 25037 |
| ChEMBL ID | CHEMBL927 |
| ChEBI ID | 3485 |
| PubChem CID | 6915944 |
| DrugBank | DB00535 |
| UNII ID | CI0FAO63WC (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,474 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
17,837 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more